Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026289 | 1.00 | ITGB3 (0.42) | ITGB3ITGAVMEN1KMT2ACCKBR | |
| SCHEMBL5025707 | 1.00 | ITGB3 (0.42) | ITGB3ITGAVMEN1KMT2ACCKBR | |
| SCHEMBL5026398 | 0.85 | PTGDR2 (0.39) | ITGB3ITGAVCCKBR | |
| SCHEMBL5025489 | 0.82 | MTNR1B (0.38) | ITGB3ITGAVMEN1KMT2ACCKBR | |
| SCHEMBL5029834 | 0.81 | ITGB3 (0.50) | ITGB3ITGAVMEN1KMT2AACE | |
| SCHEMBL5023977 | 0.81 | MEN1 (0.34) | MEN1KMT2ACCKBRACEMME | |
| SCHEMBL5025674 | 0.80 | ITGB3 (0.36) | ITGB3ITGAVCCKBRMAPTSMN1; SMN2 | |
| SCHEMBL5025671 | 0.79 | P2RY2 (0.40) | ITGB3ITGAVCCKBRMAPTSMN1; SMN2 | |
| SCHEMBL5030005 | 0.77 | ITGB3 (0.34) | ITGB3ITGAVCCKBRMAPTSMN1; SMN2 | |
| SCHEMBL5030000 | 0.77 | CCKBR (0.33) | ITGB3ITGAVCCKBRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1286673-B1 | LIGANDS OF INTEGRIN RECEPTORS | BASF AG (DE) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885MEN1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.